Radiotherapy, which is capable of inducing immunogenic cell death by exposing tumour-associated antigens/neoantigens that can be recognised by antigen-presenting cells (APCs)166 and then presented to CD8+ T cells, is currently being tested in clinical trials in combination with ICB.167. Here, CD8A is linked to neoplasm.